Last reviewed · How we verify
Meropenem-Vaborbactam
Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation.
Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation. Used for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible gram-negative bacteria.
At a glance
| Generic name | Meropenem-Vaborbactam |
|---|---|
| Also known as | Vabomere, Combination vaborbactam and meropenem, beta-lactamase inhibitor and carbapenem antibiotic, Carbavance, Meropenem 2 g-Vaborbactam 2 g |
| Sponsor | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) |
| Drug class | Carbapenem with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Meropenem is a broad-spectrum carbapenem that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor that protects meropenem from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE) enzymes, thereby restoring meropenem's activity against resistant gram-negative bacteria.
Approved indications
- Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria
- Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible gram-negative bacteria
Common side effects
- Headache
- Diarrhea
- Nausea
- Phlebitis at infusion site
- Seizures
Key clinical trials
- A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections (PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis (PHASE2)
- Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales
- Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (PHASE1)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Nosocomial Infections in ECMO Patients
- Use of New Antibiotics in Sweden
- Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: